Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use
Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use have?
Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use has 1 citations in the OpenAlex counts ScholarIQ stores.
When was Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use published?
Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use has 2025 year in the ScholarIQ index.
What is the open-access status of Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use?
Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use has closed oa status in the ScholarIQ index.
What is the DOI of Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use?
The DOI for Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use is on the source record.
What is the OpenAlex record for Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use?
The OpenAlex for Delayed Presentation of Primary Podocytopathy and Membranoproliferative Glomerulonephritis (MPGN) Pattern of Injury Secondary to Pembrolizumab and Lenvatinib Use is on the source record.